3-Bromo-5-nitropyridine | CAS:15862-30-3

We serve 3-Bromo-5-nitropyridine CAS:15862-30-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
3-Bromo-5-nitropyridine

Chemical Name:  3-Bromo-5-nitropyridine
CAS.NO:15862-30-3
Synonyms:    3-Bromo-5-nitropyridine
3-Bromo-5-Nitropyridine
3-bromanyl-5-nitro-pyridine
3-Brom-5-nitropyridin
Pyridine,3-bromo-5-nitro
 
Molecular Formula:C5H3BrN2O2
Molecular Weight:202.99400
 
Physical and Chemical Properties:
Density:1.833g/cm3
Boiling point:251.6ºC at 760mmHg
Melting point:/
Flash point:106ºC
Index of Refraction:1.614
 
Specification:
Appearance:White Crystalline Powder
Purity:≥99.0%
 
Packing:25kg/drum, can also be packaged according to customer requirements
Storage:Preserve in well-closed, light-resistant and airtight containers
Application: Pesticide intermediates, dye intermediates, flavor and fragrance intermediates, pharmaceutical intermediates



Contact us for information like 3-Bromo-5-nitropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyridine,3-bromo-5-nitro physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-bromanyl-5-nitro-pyridine Use and application,3-Brom-5-nitropyridin technical grade,usp/ep/jp grade.


Related News: Many domestic raw material pharmaceutical and intermediate manufacturing companies with strong capital and talent reserves and advanced technology and processes have developed in the country, and the competitiveness of market participants has continued to increase.N-Methoxycarbonyl-L-tert-leucine manufacturer U.S. drugmaker Gilead dominates the HIV market and it will keep up the pressure with fast-growing Biktarvy, which was approved early last year.1-ethyl-4-(4-iodophenyl)benzene supplier Beta Bionics is committed to obtaining regulatory approval and commercializing all three iLet configurations.4-Amino-6-chlorobenzene-1,3-disulfonamide vendor Fate Therapeutics, Inc. recently announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, FL.Nevertheless, many other didn’t appear to need confirmation. Posts on Weibo, China’s Twitter-like platform, purportedly showed people lining up at night outside pharmacies across China to buy Shuanghuanglian.